Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Leadership

QUOTED. 12 August 2020. Rep. James Clyburn.

  • News

Executive Summary

House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.

“It is far past time for the White House to … provide the federal leadership and comprehensive national testing strategy we need to fight this pandemic.” – James Clyburn, chairman, Select Subcommittee on Coronavirus Crisis

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Leadership
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

See All
UsernamePublicRestriction

Register

MT142568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By